Sarepta Gets An Upgrade; Cardiac, Pulmonary Function Could Provide Added Clinical Support For Exondys

By: via Benzinga
Sarepta Therapeutics Inc (NASDAQ: SRPT) presented encouraging long-term cardiac and pulmonary data at the MDA Scientific Conference. The ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.